Print
This site is intended for U.S. animal healthcare professionals
This site is intended for U.S. animal healthcare professionals
CYTOPOINT dosing chart
Dosing instructions per U.S. product label. The dose varies depending on country of licensure.
Progress exams with CYTOPOINT therapy help determine when dogs have achieved treatment success
How to store CYTOPOINT
Store vials upright, in original packaging, at 2°-8°C/36°-47°F. Do not freeze
- Prolonged exposure to higher temperature and/or direct sunlight may adversely affect potency
CYTOPOINT contains no preservatives and vials are single-use only
Vials should be discarded after puncture. Do not split vials between patients
Prepare for possible flares with long-term allergic itch treatment
Set expectations for possible flares of itch with the pet owner, and maintain open, two-way communication during treatment
If the pet owner suspects a flare, avoid over-the-phone treatment recommendations and schedule an exam for the dog
Complete an exam to identify the underlying cause of the flare (eg, fleas, dietary indiscretion, infection, seasonal allergy)
Advise the pet owner to continue CYTOPOINT treatment during the flare
Provide additional, short-term anti-pruritic relief as needed, such as APOQUEL® (oclacitinib tablet)
STUDY DESIGN
This was a randomized, placebo-controlled, masked laboratory study in 40 laboratory beagles. On Day 0, dogs received a subcutaneous injection of either placebo (n=20) or CYTOPOINT® at 2.0 mg/kg (n=20). Pruritus was induced in all dogs on study Days -7 (±2), 1 and 28 (±1) by intravenous (IV) challenge with IL-31 (2.5 μg/kg). Pruritus scores were measured by a masked observer for 120 minutes following administration of IL-31; specifically, at consecutive 1-minute intervals, "yes"/"no" decisions were made in regards to whether a pruritic behavior was displayed by each dog within the 120-minute observation period, resulting in a maximum possible total score of 120.
STUDY DESIGN
A single 2.0 mg/kg dose of CYTOPOINT® (n=50) or placebo (n=52) was administered subcutaneously on Day 0 in this randomized, double-blind, placebo-controlled study of dogs diagnosed with atopic dermatitis. The primary effectiveness endpoints were treatment success in pruritus as assessed by owners on a VAS (success defined as a ≥20 mm reduction in pruritus scores compared to Day 0) and by investigators with CADESl-03 (success defined as a ≥50% decrease in CADESl-03 score compared to Day 0).
STUDY DESIGN
A single 2.0 mg/kg dose of CYTOPOINT® (n=50) or placebo (n=52) was administered subcutaneously on Day 0 in this randomized, double-blind, placebo-controlled study of dogs diagnosed with atopic dermatitis. The primary effectiveness endpoints were treatment success in pruritus as assessed by owners on a VAS (success defined as a ≥20 mm reduction in pruritus scores compared to Day 0) and by investigators with CADESl-03 (success defined as a ≥50% decrease in CADESl-03 score compared to Day 0).
STUDY DESIGN
This study was an independent, real-world, retrospective analysis of medical records of dogs with allergic dermatitis treated with CYTOPOINT® from November 2015 to October 2016. Treatment success for owner-assessed pruritus was empirically defined as a ≥2 cm reduction in Pruritus Visual Analog Scale (PVAS) from baseline. The 135 dogs in this study included 80 with atopic dermatitis (7—seasonal, 73—non-seasonal), 10 with concurrent food allergy and atopic dermatitis, 45 with atopic dermatitis of undetermined cause, 3 lost to follow-up and 0 flea-allergic dogs (this study was completed in Fort Collins, Colorado).
STUDY DESIGN
This was a multi-centered prospective open observational Phase IV study with an objective of understanding the efficacy of 3 monthly dosages of CYTOPOINT® in dogs with atopic dermatitis (AD) (n=110). Dogs were evaluated weekly for pruritus and monthly for clinical signs of AD to understand the benefit of consecutive monthly dosing and the duration of treatment effect. Single doses were administered on study Day 0, then further on Day 30, with Day 60 dependent on clinical response. Treatment success was defined as achieving a 20 mm reduction in PVAS from baseline. Inclusion and exclusion criteria were intended to ensure enrollment of dogs with AD but without other concurrent disease or pharmaceutical treatments that could confound the study. Dogs had a documented history of non-seasonal AD or seasonal AD where prior history supported disease preferences for at least 4 months following initiation treatment.
CONTACT US
United States 
For animals. For health. For you.
This site is intended for U.S. Animal Healthcare Professionals.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2020 Zoetis Services LLC. All rights reserved.
